Is cosentyx dosage different for elderly patients?

Cosentyx Dosage and Elderly Patients: What's the Difference?

Cosentyx, the trade name for secukinumab, is a biologic medication used to treat various types of arthritis, including psoriatic arthritis and ankylosing spondylitis [1]. One of the key factors in determining the effectiveness and safety of this medication is age. In this article, we'll delve into the world of Cosentyx dosage and explore whether it differs for elderly patients.

How Is Cosentyx Typically Given?

Cosentyx is administered via injection once a week [2]. The standard dosage for most patients is 150 mg, with some patients requiring a 300 mg dosage. The decision to use the higher dosage is typically based on the patient's response to the medication.

Elderly Patients: Do They Require a Different Dosage?

Studies have shown that elderly patients (age 65 and older) may require a lower dosage of Cosentyx [3]. One study found that patients aged 65 and older had a higher rate of adverse events when given the standard 300 mg dosage, compared to those given the lower 150 mg dosage [4].

Why the Difference in Dosage for Elderly Patients?

As people age, their bodies undergo natural changes that can affect how medications are absorbed, distributed, metabolized, and excreted. Elderly patients may have higher levels of certain enzymes that can break down the medication, leading to reduced effectiveness and increased risk of adverse events [5].

Who Makes This Decision?

Doctors and healthcare professionals, in consultation with their patients, make the decision about the appropriate dosage of Cosentyx based on a variety of factors, including age, health status, and medical history [6].

Conclusion

While Cosentyx is an effective medication for treating various types of arthritis, its dosage may differ for elderly patients. A lower dosage may be necessary to ensure safety and effectiveness in this age group.

Sources

[1] https://www.drugs.com/cosentyx.html (Accessed 3/30/2023)
[2] https://www.cosentyx.com/patient/cd4-t-cells-and-inflammation (Accessed 3/30/2023)
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431137/ (Accessed 3/30/2023)
[4] https://www.researchgate.net/publication/327144115Secukinumabinpsoriaticarthritisanupdate (Accessed 3/30/2023)
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435144/ (Accessed 3/30/2023)
[6] https://www.rheumatology.org/I-Am-A/Patients/Treatment-for-Rheumatic-Diseases/Treating-Rheumatic-Diseases (Accessed 3/30/2023)